law

Please note: this document forms part of the EMCDDA's institutional record. It is based on a study carried out in 1998. The information contained within this document may no longer be correct...

This short report, Prepared by the EMCDDA at the request of the Pompidou Group Secretariat, undertakes a comparison between the national interventions in the area of substitution treatment with classified substances, and...

In the last year, there has been decriminalisation of all drug use in Portugal, a Policy Note in Belgium to decriminalise cannabis possession, and the start of the process to downgrade the...

This analysis describes and compares the different substances often referred to as "medicinal cannabis" and their methods of administration, as well as the various methods and levels of permission and control under...

All countries use legal or judicial means to grade the severity of the offence of drug possession and related actions. Frequently this is done by reference to the quantity of drugs involved...

With abuse of controlled drugs increasing, there is concern over the effects that this may have on the population. One of these effects is the possible reduction in ability to drive a...

Various studies and surveys have shown that involvement with drugs starts at an early age, and frequently before adulthood. In 1999, lifetime prevalence rates of cannabis use among 15-16 year olds in...

How international and national legislation on substitution treatment is enforced in the EU is the focus of an EMCDDA study carried out by the Catholic University of Leuven (Belgium). The study looks...

One of the targets of the EU action plan is ‘to reduce significantly over five years the prevalence of drug use, as well as new recruitment to it, particularly among young people...

Written to contribute to the European Commission's Communication on evaluation of the EU Action Plan, this paper highlights evidence of legislative activity related to new synthetic drugs as an indicator of Member...